Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results , with sales up 17.2% year on year to $794 ...

Q1 2025 Management View CEO Martine Rothblatt highlighted that United Therapeutics achieved record revenue for the quarter, marking the ninth such achievement in the past 12 quarters. She emphasized ...

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $6.29 per share. The drugmaker posted revenue of $794.4 ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00, and a low estimate of $314.00. This current average represents a 5.57% ...

Wells Fargo downgraded United Therapeutics (UTHR) to Equal Weight from Overweight with a price target of $314, down from $395.Stay Ahead of the ...

United Therapeutics maintained a strong balance sheet, with $5.03 billion in cash and investments as of March 31, 2025. The company will host a conference call later today to discuss the quarter in ...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...